Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991;34(1):37-42.
doi: 10.1007/BF01741322.

Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site

R Pellegrini  1 , F Centis, S Martignone, A Mastroianni, E Tagliabue, E Tosi, S Ménard, M I Colnaghi
Affiliations

Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site

R Pellegrini et al. Cancer Immunol Immunother. 1991.

Abstract

In this work a new monoclonal antibody (mAb), designated MGR1, which recognizes the epidermal growth factor receptor (EGF-R) binding site, is described. The main characteristic of this mAb is its ability to discriminate between cells that express normal levels of EGF-R from cells with overexpression, the detectability threshold by immunocytochemical tests being 5 x 10(4) receptors/cell of 10 microns diameter. MGR1 was found to inhibit EGF binding on the relevant target cells, and vice versa its binding was inhibited by EGF, which indicated that MGR1 recognizes the EGF receptor binding site. MGR1 exerted an inhibitory effect on both the in vitro and in vivo growth of cells with EGF-R overexpression, but had no effect on cells with a normal expression of the receptor. Tumour growth inhibition in athymic mice was also obtained on already implanted tumours. MGR1 therefore seems to be an adequate reagent for the development of immunotherapeutical approaches suitable for the treatment of tumours with EGF-R overexpression.

PubMed Disclaimer

References

    1. Abound-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst. 1988;80:1605. - PubMed
    1. Abound-Pirak E, Hurwitz E, Bellot F, Schlessinger J, Sela M. Inhibition of human tumour growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor. Proc Natl Acad Sci USA. 1989;86:3778. - PMC - PubMed
    1. Canevari S, Orlandi R, Ripamonti M, Tagliabue E, Aguanno S, Miotti S, Ménard S, Colnaghi MI. Ricin A chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro. J Natl Cancer Inst. 1985;75:831. - PubMed
    1. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem. 1987;56:881. - PubMed
    1. DePotter CR, VanDaele S, VanDeVijver MJ, Pauwels C, Maertens G, DeBoever J, Vandekerckhove D, Roels H. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology. 1989;15:362. - PubMed

Publication types

LinkOut - more resources